The Evolving Treatment Landscape for Metastatic Castration-Resistant Prostate Cancer



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  Fairmont Chicago, Millennium Park
Room Name: State Room
ChicagoIL Wednesday
Sep 7, 2016 12:00 PM
View Agenda  The Broadmoor
Room Name: Broadmoor Hall E
Colorado SpringsCO Thursday
Sep 29, 2016 7:00 AM


Presentation Slides:

Download (PDF) Click here to view the presentation slides from this symposium.

Click here to view the presentation slides from this symposium. (Coming Soon)

Program Description

Community-based clinicians are challenged to stay up to date with the rapidly diversifying treatment landscape for metastatic castration-resistant prostate cancer (mCRPC). Personalized treatment options are dependent on many factors, including knowledge of prior therapy, presence of resistance markers, bone metastases, and patient preferences. This activity will utilize clinical scenarios to demonstrate how to maximize clinical benefit by incorporating current and emerging data into practice and will provide resources to empower patients in treatment decisions.

Agenda

  1. Welcome and Introduction
  2. Clinical Case Discussions
  3. Question & Answer Session; Closing Remarks

Target Audience

This activity is intended for community-based urologists, medical oncologists, surgical oncologists, radiation oncologists, and other health care professionals involved in the treatment and care of patients with metastatic castration-resistant prostate cancer (mCRPC).

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Review the current and emerging data regarding diagnosis and management of mCRPC
  • Discuss updated guidelines for systemic therapy and survivorship care planning
  • Assess the safety and efficacy data of available therapies and the roles of biomarkers in personalizing the management of mCRPC
  • Empower patients to become active participants in their treatment decisions and health management

Steering Committee

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Co-Director, Signal Transduction Research Program
Yale School of Medicine
New Haven, CT

Oliver Sartor, MD
Medical Director, Tulane Cancer Center
C.E. & Bernadine Laborde Professor for Cancer Research
Department of Medicine and Urology
Tulane Medical School
New Orleans, LA

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement


The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit, the post-test, or evaluation, please email contact@potomacme.org.


Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. 

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias. 

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. CME certificates will be emailed to participants within 2 weeks.

There are no fees associated with this program.

Special Services

Event staff will be glad to assist you with any special needs. Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.


Provided by


Jointly provided by Potomac Center for Medical Education and Rockpointe Oncology

      

Supported by

This activity is supported by an independent educational grant from Astellas Pharma Global Development Inc. and Medivation, Inc.



Registration

  VenueCityStateDate
View Agenda  Fairmont Chicago, Millennium Park
Room Name: State Room
ChicagoIL Wednesday
Sep 7, 2016 12:00 PM
View Agenda  The Broadmoor
Room Name: Broadmoor Hall E
Colorado SpringsCO Thursday
Sep 29, 2016 7:00 AM